Telitacicept for difficult-to-treat rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests if a new medication, telitacicept, is safe and effective for people with difficult-to-treat rheumatoid arthritis. It may be an option for patients who have not found relief from other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult over 18 years old.
- You have been diagnosed with difficult-to-treat rheumatoid arthritis.
- You are willing to use effective birth control if you can become pregnant.
- You have not had any certain herbal treatments in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
This trial tests telitacicept to improve lupus nephritis (inflammation of the kidneys caused by lupus). It targets people with active kidney disease confirmed by biopsy and compares outcomes while you receive standard steroid plus mycophenolate treatment.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This trial tests a new medicine called telitacicept for people with connective tissue disease (like lupus or Sjögren's) whose platelet counts stay dangerously low despite standard treatments. It aims to raise platelet levels and reduce bleeding risk.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.